FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Ambey Laboratories IPO and Nephro Care India IPO.
Ambey Laboratories IPO is a SME Book Built Issue IPO proposed to list at NSE SME while Nephro Care India IPO is a SME Book Built Issue proposed to list at NSE SME.
Ambey Laboratories IPO | Nephro Care India IPO | |
---|---|---|
Logo | ||
Issue Category | SME | SME |
Issue Type | IPO | IPO |
Process Type | Book Built Issue | Book Built Issue |
Listing At | NSE SME | NSE SME |
Lead Managers | Fast Track Finsec Pvt Ltd | Corporate Capitalventures Pvt Ltd |
Registrar | Link Intime India Private Ltd | Bigshare Services Pvt Ltd |
Market Maker | Nikunj Stock Brokers Limited | Ss Corporate Securities Limited |
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | Anchor Investor | Anchor Investor |
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Ambey Laboratories IPO is up to ₹44.68 Cr whereas the issue size of the Nephro Care India IPO is up to ₹41.26 Cr. The final issue price of Ambey Laboratories IPO is ₹68.00 per share and of Nephro Care India IPO is ₹90.00 per share.
Ambey Laboratories IPO | Nephro Care India IPO | |
---|---|---|
Face Value | ₹10 per share | ₹10 per share |
Issue Price (Lower) | ₹65.00 per share | ₹85.00 per share |
Issue Price (Upper) | ₹68.00 per share | ₹90.00 per share |
Issue Price (Final) | ₹68.00 per share | ₹90.00 per share |
Discount (Retail) | ||
Discount (Employee) | ||
Market Lot Size | 2000 shares | 1600 shares |
Fresh Issue Size | 62,58,000 shares | 45,84,000 shares |
Fresh Issue Size (Amount) | up to ₹42.55 Cr | up to ₹41.26 Cr |
OFS Issue Size | 3,12,000 shares | |
OFS Issue Size (Amount) | up to ₹2.12 Cr | |
Issue Size Total | 65,70,000 shares | 45,84,000 shares |
Issue Size Total (Amount) | up to ₹44.68 Cr | up to ₹41.26 Cr |
Ambey Laboratories IPO opens on Jul 04, 2024, while Nephro Care India IPO opens on Jun 28, 2024. The closing date of Ambey Laboratories IPO and Nephro Care India IPO is Jul 08, 2024, and Jul 02, 2024, respectively.
Ambey Laboratories IPO | Nephro Care India IPO | |
---|---|---|
Anchor Bid Date | Jul 03, 2024 | Jun 27, 2024 |
Issue Open | Jul 04, 2024 | Jun 28, 2024 |
Issue Close | Jul 08, 2024 | Jul 02, 2024 |
Basis Of Allotment (Tentative) | Jul 09, 2024 | Jul 03, 2024 |
Initiation of Refunds (Tentative) | Jul 10, 2024 | Jul 04, 2024 |
Credit of Share (Tentative) | Jul 10, 2024 | Jul 04, 2024 |
Listing date (Tentative) | Jul 11, 2024 | Jul 05, 2024 |
Anchor Lockin End date 1 | Aug 08, 2024 | Aug 02, 2024 |
Anchor Lockin End date 2 | Oct 07, 2024 | Oct 01, 2024 |
Ambey Laboratories IPO P/E ratio is 27.81, as compared to Nephro Care India IPO P/E ratio of 55.15.
Ambey Laboratories IPO | Nephro Care India IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial | Ambey Laboratories Limited Financial Information (Restated)
|
Nephro Care India Limited Financial Information (Restated)Nephro Care India Limited's revenue increased by 398.84% and profit after tax (PAT) rose by 19920.41% between the financial year ending with March 31, 2023 and March 31, 2022.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 94.97% | 85.02% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | 69.90% | 61.39% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | 27.81 | 55.15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ₹171.64 Cr. | ₹148.38 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROE | 20.80%% | 41.57%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROCE | 13.14%% | 36.56%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | 0.58 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EPS | ₹2.44 | ₹1.63 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RoNW | 20.80%% | 24.42%% |
In the Ambey Laboratories IPO retail investors (RII) are offered 21,84,000 shares while in Nephro Care India IPO retail investors are offered 21,84,000 shares. Qualified institutional buyers (QIB) are offered 12,52,000 shares in Ambey Laboratories IPO and 8,25,600 shares in Nephro Care India IPO.
Ambey Laboratories IPO | Nephro Care India IPO | |
---|---|---|
Anchor Investor Reserveration | 18,72,000 shares | 12,38,400 shares |
Market Maker Reserveration | 3,30,000 shares | 2,30,400 shares |
QIB | 12,52,000 shares | 8,25,600 shares |
NII | 6,06,001 shares | 6,19,200 shares |
RII | 21,84,000 shares | 14,44,800 shares |
Employee | 0 shares | 0 shares |
Others | ||
Total | 40,42,001 shares | 31,15,200 shares |
Ambey Laboratories IPO subscribed 173.18x in total, whereas Nephro Care India IPO subscribed 715.78x.
Ambey Laboratories IPO | Nephro Care India IPO | |
---|---|---|
QIB (times) | 61.90x | 245.14x |
NII (times) | 324.22x | 1,787.19x |
Big NII (times) | ||
Small NII (times) | ||
RII (times) | 195.06x | 634.12x |
Employee (times) | ||
Other (times) | ||
Total (times) | 173.18x | 715.78x |
Add a public comment...
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|